Chemotherapy plus tazemetostat for advanced nasal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of chemotherapy and a targeted drug called tazemetostat for a rare type of nasal cancer that has not spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 40 kg.
- You have a confirmed diagnosis of locally advanced SMARCB1-deficient sinonasal carcinoma (a rare nasal cancer).
- Your cancer has not spread to other parts of the body.
- You have not had certain cancer treatments within the last few weeks (varies by type).
- Your blood counts, liver, and kidney function are within acceptable levels.
- You are willing to use effective contraception if you or your partner can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the targeted drug becotatug vedotin with chemo can shrink recurrent adenoid cystic sinus tumors that can't be fully removed by surgery. It's for people whose tumors have a specific protein called EGFR.
This study looks at whether surgery followed by radiation helps people with a specific type of sinus cancer called adenoid cystic carcinoma that has grown into nearby tissues. It aims to see how well this treatment works and how safe it is.
This Phase 2 study tests a treatment plan that combines immunotherapy with chemotherapy and chemoradiation for advanced squamous cell cancer in the nasal cavity or sinuses. It aims to improve cancer control in people who are newly diagnosed and have not had prior treatment for this cancer.
This trial tests a combination of chemotherapy (docetaxel and cisplatin) plus two immunotherapy drugs before surgery for people with newly diagnosed, locally advanced sinonasal cancer. The goal is to see if this combination helps shrink the tumor and improves the chance of successful surgery.
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
This trial tests pembrolizumab (an immune therapy) for locally advanced sinonasal cancer that can still be cured with local treatments. It aims to improve outcomes by helping your immune system better fight the tumor.
Hear when a new Sinonasal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.